Search Results
Search for other papers by Raja Padidela in
Google Scholar
PubMed
Search for other papers by Moira S Cheung in
Google Scholar
PubMed
Search for other papers by Vrinda Saraff in
Google Scholar
PubMed
Search for other papers by Poonam Dharmaraj in
Google Scholar
PubMed
X-linked hypophosphataemia (XLH) is caused by a pathogenic variant in the PHEX gene, which leads to elevated circulating FGF23. High FGF23 causes hypophosphataemia, reduced active vitamin D concentration and clinically manifests as rickets in children and osteomalacia in children and adults. Conventional therapy for XLH includes oral phosphate and active vitamin D analogues but does not specifically treat the underlying pathophysiology of elevated FGF23-induced hypophosphataemia. In addition, adherence to conventional therapy is limited by frequent daily dosing and side effects such as gastrointestinal symptoms, secondary hyperparathyroidism and nephrocalcinosis. Burosumab, a recombinant human IgG1 MAB that binds to and inhibits the activity of FGF23, is administered subcutaneously every 2 weeks. In clinical trials (phase 2 and 3) burosumab was shown to improve phosphate homeostasis that consequently resolves the skeletal/non-skeletal manifestations of XLH. Burosumab was licensed in Europe (February 2018) with the National Institute for Health and Care Excellence, UK approving use within its marketing authorisation in October 2018. In this publication, the British Paediatric and Adolescent Bone Group (BPABG) reviewed current evidence and provide expert recommendations for care pathway and management of XLH with burosumab.
Search for other papers by Kaiyu Pan in
Google Scholar
PubMed
Search for other papers by Chengyue Zhang in
Google Scholar
PubMed
Search for other papers by Xiaocong Yao in
Google Scholar
PubMed
Search for other papers by Zhongxin Zhu in
Google Scholar
PubMed
Aim
Ensuring adequate calcium (Ca) intake during childhood and adolescence is critical to acquire good peak bone mass to prevent osteoporosis during older age. As one of the primary strategies to build and maintain healthy bones, we aimed to determine whether dietary Ca intake has an influence on bone mineral density (BMD) in children and adolescents.
Methods
We conducted a cross-sectional study composed of 10,092 individuals from the National Health and Nutrition Examination Survey (NHANES). Dietary Ca intake and total BMD were taken as independent and dependent variables, respectively. To evaluate the association between them, we conducted weighted multivariate linear regression models and smooth curve fittings.
Results
There was a significantly positive association between dietary Ca intake and total BMD. The strongest association was observed in 12–15 year old whites, 8–11 year old and 16–19 year old Mexican Americans, and 16–19 year old individuals from other race/ethnicity, in whom each quintile of Ca intake was increased. We also found that there were significant inflection points in females, blacks, and 12–15 year old adolescents group, which means that their total BMD would decrease when the dietary Ca intake was more than 2.6–2.8 g/d.
Conclusions
This cross-sectional study indicated that a considerable proportion of children and adolescents aged 8–19 years would attain greater total BMD if they increased their dietary Ca intake. However, higher dietary Ca intake (more than 2.6–2.8 g/d) is associated with lower total BMD in females, blacks, and 12–15 year old adolescents group.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Mirjana Doknic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Marko Stojanovic in
Google Scholar
PubMed
Institute of Medical Statistics and Informatics, Belgrade, Serbia
Search for other papers by Ivan Soldatovic in
Google Scholar
PubMed
Search for other papers by Tatjana Milenkovic in
Google Scholar
PubMed
University Children’s Clinic, Belgrade, Serbia
Search for other papers by Vera Zdravkovic in
Google Scholar
PubMed
University Children’s Clinic, Belgrade, Serbia
Search for other papers by Maja Jesic in
Google Scholar
PubMed
Search for other papers by Sladjana Todorovic in
Google Scholar
PubMed
Mother and Child Health Care Institute of Serbia ‘Dr Vukan Cupic’, Belgrade, Serbia
Search for other papers by Katarina Mitrovic in
Google Scholar
PubMed
Mother and Child Health Care Institute of Serbia ‘Dr Vukan Cupic’, Belgrade, Serbia
Search for other papers by Rade Vukovic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Search for other papers by Dragan Savic in
Google Scholar
PubMed
Search for other papers by Mihajlo Milicevic in
Google Scholar
PubMed
Search for other papers by Aleksandar Stanimirovic in
Google Scholar
PubMed
Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia
Search for other papers by Vojislav Bogosavljevic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Sandra Pekic in
Google Scholar
PubMed
Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Emilija Manojlovic-Gacic in
Google Scholar
PubMed
Search for other papers by Aleksandar Djukic in
Google Scholar
PubMed
Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia
Search for other papers by Danica Grujicic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Milan Petakov in
Google Scholar
PubMed
Objective
To analyze metabolic parameters, body composition (BC), and bone mineral density (BMD) in childhood-onset GH deficiency (COGHD) patients during the transition period (TP).
Design
Single- center, retrospective study was performed on 170 consecutive COGHD patients (age 19.2 ± 2.0 years, range 16–25) transferred after growth completion from two pediatric clinics to the adult endocrine unit. Two separate analyses were performed: (i) cross-sectional analysis of hormonal status, metabolic parameters, BC, and BMD at first evaluation after transfer from pediatrics to the adult department; (ii) longitudinal analysis of BC and BMD dynamics after 3 years of GH replacement therapy (rhGH) in TP.
Results
COGHD was of a congenital cause (CONG) in 50.6% subjects, tumor-related (TUMC) in 23.5%, and idiopathic (IDOP) in 25.9%. TUMC patients had increased insulin and lipids levels (P < 0.01) and lower Z score at L-spine (P < 0.05) compared to CONG and IDOP groups. Patients treated with rhGH in childhood demonstrated lower fat mass and increased BMD compared to the rhGH-untreated group (P < 0.01). Three years of rhGH after growth completion resulted in a significant increase in lean body mass (12.1%) and BMD at L-spine (6.9%), parallel with a decrease in FM (5.2%).
Conclusion
The effect of rhGH in childhood is invaluable for metabolic status, BC, and BMD in transition to adulthood. Tumor-related COGHD subjects are at higher risk for metabolic abnormalities, alteration of body composition, and decreased BMD, compared to those with COGHD of other causes. Continuation of rhGH in transition is important for improving BC and BMD in patients with persistent COGHD.
